0001209191-18-004394.txt : 20180118 0001209191-18-004394.hdr.sgml : 20180118 20180118185755 ACCESSION NUMBER: 0001209191-18-004394 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180116 FILED AS OF DATE: 20180118 DATE AS OF CHANGE: 20180118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doogan Declan CENTRAL INDEX KEY: 0001704234 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38080 FILM NUMBER: 18535103 MAIL ADDRESS: STREET 1: C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP STREET 2: 234 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 234 CHURCH STREET, SUITE 304 CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 234 CHURCH STREET, SUITE 304 CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-16 0 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001704234 Doogan Declan C/O BIOHAVEN PHARMACEUTICALS 234 CHURCH STREET NEW HAVEN CT 06510 1 0 0 0 Common Shares 2018-01-16 4 S 0 37033 26.59 D 1487027 I By The Declan Doogan 2014 Trust Common Shares 2018-01-16 4 S 0 1834 27.07 D 1485193 I By The Declan Doogan 2014 Trust Common Shares 2018-01-17 4 S 0 23726 26.19 D 1461467 I By The Declan Doogan 2014 Trust Common Shares 2018-01-17 4 S 0 37530 26.84 D 1423937 I By The Declan Doogan 2014 Trust Common Shares 2018-01-18 4 S 0 4546 26.71 D 1419391 I By The Declan Doogan 2014 Trust Common Shares 2018-01-18 4 S 0 5618 27.87 D 1413773 I By The Declan Doogan 2014 Trust Common Shares 2018-01-18 4 S 0 17671 28.71 D 1396102 I By The Declan Doogan 2014 Trust Common Shares 2018-01-18 4 S 0 100 29.22 D 1396002 I By The Declan Doogan 2014 Trust Common Shares 463913 D These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 - $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Includes 346,002 shares received by the Reporting Person from by Portage Biotech Inc. as a distribution in kind on a pro rata basis to its shareholders, effective January 15, 2017, which transaction was not required to be reported under SEC rules (the "Distribution"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 - $27.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.64 - $26.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.64 - $27.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 - $26.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.20 - $28.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.21 - $29.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) to this Form 4. Represents shares received directly by the Reporting Person in the Distribution. /s/ Darren K. DeStefano, Attorney-in-fact 2018-01-18